Envestnet Asset Management Inc. Sells 7,591 Shares of Humana Inc. (NYSE:HUM)

Envestnet Asset Management Inc. reduced its holdings in Humana Inc. (NYSE:HUM - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,734 shares of the insurance provider's stock after selling 7,591 shares during the period. Envestnet Asset Management Inc. owned about 0.10% of Humana worth $31,139,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. FPC Investment Advisory Inc. acquired a new stake in Humana in the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC acquired a new position in Humana during the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA raised its holdings in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Humana in the fourth quarter worth about $33,000. Finally, Atwood & Palmer Inc. boosted its stake in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after acquiring an additional 60 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on HUM. Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Mizuho upped their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Robert W. Baird lifted their price objective on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday. Barclays raised their target price on Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a report on Friday, April 11th. Finally, Truist Financial increased their price objective on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research report on Friday, April 11th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $284.90.

Humana Price Performance

Shares of HUM stock traded down $21.20 during trading hours on Friday, reaching $264.41. 3,670,273 shares of the company were exchanged, compared to its average volume of 1,756,462. The company has a market cap of $31.91 billion, a price-to-earnings ratio of 26.57, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock's fifty day moving average is $265.75 and its two-hundred day moving average is $269.97. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. Humana's dividend payout ratio is currently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.